Analysis of deep brain stimulation (DBS) costs: An observational study on Italian patients;Analisi dei costi della stimolazione cerebrale profonda (DBS) nella malattia di Parkinson: Uno studio osservazionale su pazienti italiani

PharmacoEconomics - Italian Research Articles

Volumn 4, Issue 2, 2002, Pages 65-79

  Gerzeli, S ^a   Cavallo, Maria C ^b   Caprari, F ^c   Ponzi, P ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b BOCCONI UNIVERSITY   (Italy)

^c Medtronic Italia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; AGED; ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; ECONOMIC EVALUATION; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; ITALY; MALE; PARKINSON DISEASE; PROSPECTIVE STUDY; QUESTIONNAIRE; RATING SCALE; SYMPTOM; TREATMENT OUTCOME;

EID: 0036400122     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03320596     Document Type: Article

References (41)

1. Associazione Italiana Parkinson. Guida alla Malattia di Parkinson. Lucca Viareggio: J. Medical Books Edizioni, 2000
2. Whetten-Goldstein K, Sloan F, Kulas E, et al. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997; 45: 844-9
3. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984; 16: 278-82
4. Sutcliffe RL, Prior R, Mawby B, Mc Quillan WJ. Parkinson's Disease in the district of the Northampton Health Autority, United Kingdom. A study of prevalence and disability. Acta Neurol Scand 1985; 72: 363-79
5. Hoen MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1983; 19 (suppl.): 253-64
6. Hauser RA, Zesiewicz TA. Complications of Long-Term Therapy in Parkinson's Disease. Parkinon's Disease: Questions and Answers. 2nd ed. Coral Springs, Florida USA/Hampshire, England: Merit Publishing International, 1997: 79-85
7. Mones RJ, Elizan TS, Siegel GJ. Analysis of L-dopa induced dyskinesias in 51 patients with parkinsonism. J Neurol Neurosurg Psychiatry 1971; 34: 668-73
8. Speelman JD, Bosch DA. Resurgence of functional neurosurgery for Parkinson's disease: a historical perspective. Mov Disord 1998; 13 (3); 582-8
9. Lang AE. Widner H. Deep Brain Stimulation for Parkinson's disease: patient selection and evaluation. Mov Disord 2002; 17 (suppl. 3): S94-S101
10. Dodel RC, Singer M, Kohne-Volland R, et al. The economic impact of Parkinson's disease. An estimation based on a 3-months prospective analysis. Pharmacoeconomics 1998; 14 (3): 299-312
11. Schuurman PR, Bosch DA, Bossuyt PM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Mod 2000; 342 (7): 461-8
12. Grill WM, McIntyre CC. Extracellular excitation of central neurons: implications for the mechanisms of deep brain stimulation. Thalamus & Related Systems 2001; 1 (3): 269-77
13. Dostrovsky JO, Lozano AM. Mechanism of Deep Brain Stimulation. Mov Disord 2002; 17 (suppl. 3): 63-8
14. Olanow CW, Brin MF, Obeso JA. The role of deep brain stimulation as a surgical treatment for Parkinson Disease. Neurology 2000; 55 (suppl. 6): 60-6
15. Pollack P, Fraix V, Krack P, et al. Treatment results: Parkinson Disease. Movement Disorders 2002; 17 (suppl. 3): 75-83
16. Obeso JA, Rodriguez MC, Gorospe A, et al. Surgical treatment for Parkinson's disease. Baillieres Clin Neurol 1997; 6: 125-45
17. Moro E, Scerrati M, Romito LM, et al. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 1999; 53 (1): 85-90
18. Dodel RC, Eggert K, Singer MS, et al. Cost of drug treatment in Parkinson's disease. Mov Disord 1998; 13 (2): 249-54
19. Koller WC, Glatt S, Veter-Overfield B, Hassanein R. Falls and Parkinson's Disease. Clin Neuropharmacol 1989; 12(2): 98-105
20. O'Reilly F, Finnan F, Allwright S, et al. The effects of caring for a spouse with Parkinson's disease on social, psychological and physical well-being. Br J Gen Pract 1996; 46: 507-12
21. Marchese E, Vichi MC. Un utilizzo del percorso del paziente: la valorizzazione economica del trattamento chirurgico della malattia di Parkinson. Mecosan 2000; 36:55-78
22. Louis ED, Lynch T, Marder K, Fahn S. Reliability of patient completion of the historical section of the Unified Parkinson's Disease Rating Scale. Mov Disord 1996; 11: 185-92
23. Mahoney FI, Barthel DW. Functional evaluation. The Barthel Index. Maryland State Medical Journal 1965; 14: 61-5
24. Drummond MF, O'Brein B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press, 1997
25. Gold MR, Russell LB, Siegel JE, Weinstein MC. Cost effectiveness in health and medicine. Oxford: Oxford University Press, 1996
26. Cavallo MC, Tarricone R. La valutazione del costo sociale delle malattie. Mecosan 1996; 17: 8-16
27. Anthony RN, Young DW. Management control nonprofit organizations. 5th ed. Homewood IL: Irwin, 1988
28. Agliati M. La contabilità direzionale: metodologie di misurazione dei costi di produzione. Milano: Cusl, 1987
29. L'Informatorie Farmaceutico. Milano: OEMF, 1999
30. Nomenclatore Tariffario. Ministero della Sanità. Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del SSN e relative tariffe. DM 22 Luglio 1996
31. Casati G. II percorso del paziente. La gestione per processi in sanità. Milano: EGEA, 1999
32. Francesconi A, Maggioni S, Motta M, et al. La valutazione dell'equilibrio economico della Unità del Dolore e delle Cure Palliative dell'Ospedale della USL di Garbagnate. Mecosan 1997; 23: 93-110
33. Garattini L, Tediosi F, Ghislandi S, et al. How do Italian pharmacoeconomists evaluate indirect costs? Value Health 2000; 3: 270-6
34. Banca d'Italia. Note metodologiche e informazioni statistiche. I bilanci delle famiglie italiane nell'anno 1997. Supplemento al Bollettino Statistico 1999
35. Cavallo MC, Fattore G. The economic and social burden of Alzheimer disease on families in the Lombardy region of Italy. Alzheimer Dis Assoc Disord 1997; 11: 184-90
36. Amato MP, Battaglia MA, Caputo D, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol 2002; 249(2): 152-63
37. Delvecchio F. Statistics per la ricerca sociale. Bari: Caccucci, 1999
38. Glanz A. Statistica per discipline biomediche. Milano: McGraw-Hill, 1997
39. Dodel RC, Eggert K, Oertel WH. Economical research on Parkinson's disease: a review of the literature. Eur J Neurol 1999: 6(2): S3-S15
40. Benabid AL, Benazzouz A, Hoffmann D, et al. Long-term electrical inhibition of deep brain targets in movement disorders. Mov Disord 1998; 13(3): 119-25
41. Keranen T, Kaakkola S, Sotaniemi K and the EcoPD Study Group. Economic burden and quality of life impairment increase with severity of Parkinson's disease - A health economic study of PD patients in Finland. Abstract presented at the XIV International Congress on Parkinson's Disease, July 27 - August 1, 2001, Helsinky, Finland